Results of Xpert® MTB/RIF implementation in Kyrgyzstan

G. Kurbaniyazova, M. Joncevska, S. Kalon, G. Kalmambetova, T. Mohr, A. Toktogonova, K. Takieva, K. M. Monirul Islam, F. Luelmo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

INT RODUC T ION: In July 2012, the United States Agency for International Development (USAID) Quality Health Care Project introduced the Xpertw MTB/RIF assay at the facility level of the primary health care system in Kyrgyzstan. This study analysed the results of the implementation of Xpert. MATERIALS AND METHODS : Test results from 2734 patients from July 2012 to December 2014 were analysed. The sensitivity and specificity of Xpert in routine programme conditions were evaluated using culture and phenotypic drug susceptibility testing (DST) as gold standard. Contribution to early start of treatment for multidrug-resistant tuberculosis (MDR-TB) was expressed as the median time between availability of the test result and start of treatment. RE SULT S : Compared to culture, the sensitivity and specificity of Xpert were respectively 92.7% and 90.4%. For the detection of rifampicin (RMP) resistance, Xpert sensitivity and specificity were respectively 90.1% and 90.7%. The median time to initiation of MDR-TB treatment decreased to 10 days (interquartile range [IQR] 6-16) in 2014 from 20 days (IQR 12-40, P , 0.001) in 2013. CONCLUS ION: The Xpert assay demonstrated good agreement in the detection of both Mycobacterium tuberculosis and RMP-resistant pulmonary TB in routine clinical practice. Although Xpert improved the time to treatment initiation from 2013 to 2014, more efforts are needed to further reduce this delay.

Original languageEnglish (US)
Pages (from-to)333-337
Number of pages5
JournalInternational Journal of Tuberculosis and Lung Disease
Volume21
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Kyrgyzstan
Multidrug-Resistant Tuberculosis
Rifampin
Sensitivity and Specificity
United States Agency for International Development
Quality of Health Care
Therapeutics
Mycobacterium tuberculosis
Health Status
Primary Health Care
Delivery of Health Care
Lung
Pharmaceutical Preparations

Keywords

  • Kyrgyzstan
  • Mycobacterium tuberculosis
  • Routine
  • Time to treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Kurbaniyazova, G., Joncevska, M., Kalon, S., Kalmambetova, G., Mohr, T., Toktogonova, A., ... Luelmo, F. (2017). Results of Xpert® MTB/RIF implementation in Kyrgyzstan. International Journal of Tuberculosis and Lung Disease, 21(3), 333-337. https://doi.org/10.5588/ijtld.16.0191

Results of Xpert® MTB/RIF implementation in Kyrgyzstan. / Kurbaniyazova, G.; Joncevska, M.; Kalon, S.; Kalmambetova, G.; Mohr, T.; Toktogonova, A.; Takieva, K.; Monirul Islam, K. M.; Luelmo, F.

In: International Journal of Tuberculosis and Lung Disease, Vol. 21, No. 3, 01.03.2017, p. 333-337.

Research output: Contribution to journalArticle

Kurbaniyazova, G, Joncevska, M, Kalon, S, Kalmambetova, G, Mohr, T, Toktogonova, A, Takieva, K, Monirul Islam, KM & Luelmo, F 2017, 'Results of Xpert® MTB/RIF implementation in Kyrgyzstan', International Journal of Tuberculosis and Lung Disease, vol. 21, no. 3, pp. 333-337. https://doi.org/10.5588/ijtld.16.0191
Kurbaniyazova G, Joncevska M, Kalon S, Kalmambetova G, Mohr T, Toktogonova A et al. Results of Xpert® MTB/RIF implementation in Kyrgyzstan. International Journal of Tuberculosis and Lung Disease. 2017 Mar 1;21(3):333-337. https://doi.org/10.5588/ijtld.16.0191
Kurbaniyazova, G. ; Joncevska, M. ; Kalon, S. ; Kalmambetova, G. ; Mohr, T. ; Toktogonova, A. ; Takieva, K. ; Monirul Islam, K. M. ; Luelmo, F. / Results of Xpert® MTB/RIF implementation in Kyrgyzstan. In: International Journal of Tuberculosis and Lung Disease. 2017 ; Vol. 21, No. 3. pp. 333-337.
@article{aa09bdd7600f4d848940469086533e14,
title = "Results of Xpert{\circledR} MTB/RIF implementation in Kyrgyzstan",
abstract = "INT RODUC T ION: In July 2012, the United States Agency for International Development (USAID) Quality Health Care Project introduced the Xpertw MTB/RIF assay at the facility level of the primary health care system in Kyrgyzstan. This study analysed the results of the implementation of Xpert. MATERIALS AND METHODS : Test results from 2734 patients from July 2012 to December 2014 were analysed. The sensitivity and specificity of Xpert in routine programme conditions were evaluated using culture and phenotypic drug susceptibility testing (DST) as gold standard. Contribution to early start of treatment for multidrug-resistant tuberculosis (MDR-TB) was expressed as the median time between availability of the test result and start of treatment. RE SULT S : Compared to culture, the sensitivity and specificity of Xpert were respectively 92.7{\%} and 90.4{\%}. For the detection of rifampicin (RMP) resistance, Xpert sensitivity and specificity were respectively 90.1{\%} and 90.7{\%}. The median time to initiation of MDR-TB treatment decreased to 10 days (interquartile range [IQR] 6-16) in 2014 from 20 days (IQR 12-40, P , 0.001) in 2013. CONCLUS ION: The Xpert assay demonstrated good agreement in the detection of both Mycobacterium tuberculosis and RMP-resistant pulmonary TB in routine clinical practice. Although Xpert improved the time to treatment initiation from 2013 to 2014, more efforts are needed to further reduce this delay.",
keywords = "Kyrgyzstan, Mycobacterium tuberculosis, Routine, Time to treatment",
author = "G. Kurbaniyazova and M. Joncevska and S. Kalon and G. Kalmambetova and T. Mohr and A. Toktogonova and K. Takieva and {Monirul Islam}, {K. M.} and F. Luelmo",
year = "2017",
month = "3",
day = "1",
doi = "10.5588/ijtld.16.0191",
language = "English (US)",
volume = "21",
pages = "333--337",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "3",

}

TY - JOUR

T1 - Results of Xpert® MTB/RIF implementation in Kyrgyzstan

AU - Kurbaniyazova, G.

AU - Joncevska, M.

AU - Kalon, S.

AU - Kalmambetova, G.

AU - Mohr, T.

AU - Toktogonova, A.

AU - Takieva, K.

AU - Monirul Islam, K. M.

AU - Luelmo, F.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - INT RODUC T ION: In July 2012, the United States Agency for International Development (USAID) Quality Health Care Project introduced the Xpertw MTB/RIF assay at the facility level of the primary health care system in Kyrgyzstan. This study analysed the results of the implementation of Xpert. MATERIALS AND METHODS : Test results from 2734 patients from July 2012 to December 2014 were analysed. The sensitivity and specificity of Xpert in routine programme conditions were evaluated using culture and phenotypic drug susceptibility testing (DST) as gold standard. Contribution to early start of treatment for multidrug-resistant tuberculosis (MDR-TB) was expressed as the median time between availability of the test result and start of treatment. RE SULT S : Compared to culture, the sensitivity and specificity of Xpert were respectively 92.7% and 90.4%. For the detection of rifampicin (RMP) resistance, Xpert sensitivity and specificity were respectively 90.1% and 90.7%. The median time to initiation of MDR-TB treatment decreased to 10 days (interquartile range [IQR] 6-16) in 2014 from 20 days (IQR 12-40, P , 0.001) in 2013. CONCLUS ION: The Xpert assay demonstrated good agreement in the detection of both Mycobacterium tuberculosis and RMP-resistant pulmonary TB in routine clinical practice. Although Xpert improved the time to treatment initiation from 2013 to 2014, more efforts are needed to further reduce this delay.

AB - INT RODUC T ION: In July 2012, the United States Agency for International Development (USAID) Quality Health Care Project introduced the Xpertw MTB/RIF assay at the facility level of the primary health care system in Kyrgyzstan. This study analysed the results of the implementation of Xpert. MATERIALS AND METHODS : Test results from 2734 patients from July 2012 to December 2014 were analysed. The sensitivity and specificity of Xpert in routine programme conditions were evaluated using culture and phenotypic drug susceptibility testing (DST) as gold standard. Contribution to early start of treatment for multidrug-resistant tuberculosis (MDR-TB) was expressed as the median time between availability of the test result and start of treatment. RE SULT S : Compared to culture, the sensitivity and specificity of Xpert were respectively 92.7% and 90.4%. For the detection of rifampicin (RMP) resistance, Xpert sensitivity and specificity were respectively 90.1% and 90.7%. The median time to initiation of MDR-TB treatment decreased to 10 days (interquartile range [IQR] 6-16) in 2014 from 20 days (IQR 12-40, P , 0.001) in 2013. CONCLUS ION: The Xpert assay demonstrated good agreement in the detection of both Mycobacterium tuberculosis and RMP-resistant pulmonary TB in routine clinical practice. Although Xpert improved the time to treatment initiation from 2013 to 2014, more efforts are needed to further reduce this delay.

KW - Kyrgyzstan

KW - Mycobacterium tuberculosis

KW - Routine

KW - Time to treatment

UR - http://www.scopus.com/inward/record.url?scp=85015256113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015256113&partnerID=8YFLogxK

U2 - 10.5588/ijtld.16.0191

DO - 10.5588/ijtld.16.0191

M3 - Article

VL - 21

SP - 333

EP - 337

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 3

ER -